337 related articles for article (PubMed ID: 29208938)
1. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.
Meyers DE; Thakur S; Thirukkumaran CM; Morris DG
Blood Cancer J; 2017 Dec; 7(12):640. PubMed ID: 29208938
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S
Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V; Costa F; Donofrio G; Giuliani N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668361
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
5. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
7. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
8. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.
Innao V; Rizzo V; Allegra AG; Musolino C; Allegra A
Curr Oncol; 2020 Dec; 28(1):159-183. PubMed ID: 33704184
[TBL] [Abstract][Full Text] [Related]
10. Optimizing oncolytic virotherapy in cancer treatment.
Harrington K; Freeman DJ; Kelly B; Harper J; Soria JC
Nat Rev Drug Discov; 2019 Sep; 18(9):689-706. PubMed ID: 31292532
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
12. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
13. Clinical landscape of oncolytic virus research in 2020.
Macedo N; Miller DM; Haq R; Kaufman HL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046622
[TBL] [Abstract][Full Text] [Related]
14. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
[TBL] [Abstract][Full Text] [Related]
15. Systemic virotherapy for multiple myeloma.
Oliva S; Gambella M; Boccadoro M; Bringhen S
Expert Opin Biol Ther; 2017 Nov; 17(11):1375-1387. PubMed ID: 28796556
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Viruses: Therapeutics With an Identity Crisis.
Breitbach CJ; Lichty BD; Bell JC
EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
[TBL] [Abstract][Full Text] [Related]
17. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Neri P; Bahlis NJ; Lonial S
Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.
Deng H; Tang N; Stief AE; Mehta N; Baig E; Head R; Sleep G; Yang XZ; McKerlie C; Trudel S; Stewart AK; McCart JA
Leukemia; 2008 Dec; 22(12):2261-4. PubMed ID: 18509356
[No Abstract] [Full Text] [Related]
20. Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.
Bastin D; Walsh SR; Al Saigh M; Wan Y
Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
